A decoy mutant ACE2 designed to reduce COVID-19

The need for new coronavirus disease 2019 (COVID-19) therapeutic strategies continues, especially as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge. Zhang and colleagues elegantly engineered a mutant angiotensin-converting enzyme 2 (ACE2) that competitively binds SARS-C...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Trends in pharmacological sciences (Regular ed.) 2022-09, Vol.43 (9), p.703-705
Hauptverfasser:	Maishan, Mazharul, Lim, Diana L., Zimmerman, Guy A., Matthay, Michael A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin-Converting Enzyme 2 - genetics Angiotensin-Converting Enzyme 2 - metabolism Animals ARDS COVID-19 - prevention & control COVID-19 therapy Humans Mice Protein Engineering SARS-CoV-2 Spike Glycoprotein, Coronavirus - metabolism Spotlight viral pneumonia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!